1. Signaling Pathways
  2. Cytoskeleton
  3. Gap Junction Protein

Gap Junction Protein

Gap junction (GJ) channels span the plasma membranes of adjacent cells and are formed by the docking of two hemichannels (connexons) oligomerized from connexin (Cx) proteins, which consist of 21 distinct isoforms. GJs provide a direct pathway for cell-to-cell electrical signaling and metabolic communication, allowing the passage of small ions, amino acids, metabolites, tetraethylammonium and signaling molecules such as cAMP, IP3, siRNA and small peptide.

Gap junction channels provide the basis for intercellular communication in the cardiovascular system for maintenance of the normal cardiac rhythm, regulation of vascular tone and endothelial function as well as metabolic interchange between the cells. In the heart, GJs mediate electrical coupling between cardiac myocytes, forming the cell-to-cell pathways for orderly spread of the wave of electrical excitation responsible for synchronous contraction. Gap junctions also play an important role in the control of bladder contractile response and in the regulation of various immune inflammatory processes.

Gap Junction Protein Related Products (22):

Cat. No. Product Name Effect Purity
  • HY-B1320
    Meclofenamic acid sodium
    Inhibitor 99.86%
    Meclofenamic acid (Meclofenamate) sodium is a nonsteroidal anti-inflammatory drug (NSAID) approved for use in arthritis (osteo and rheumatoid), analgesia (mild to moderate pain), dysmenorrhea, and heavy menstrual blood loss (menorrhagia). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat mass and obesity-associated (FTO) enzyme inhibitor.
  • HY-B1367
    Carbenoxolone disodium
    Inhibitor 99.88%
    Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11β-HSD and bacterial 3α, 20β-HSD. Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication. Carbenoxolone disodium is used for the study of peptic, esophageal and oral ulceration and inflammation. Carbenoxolone disodium inhibits Vaccinia virus replication.
  • HY-P0139
    Gap 27
    Inhibitor 98.07%
    Gap 27, a synthetic connexin43 mimetic peptide, is a gap junction inhibitor. Gap 27 possesses conserved sequence homology to a portion of the second extracellular loop leading into the fourth transmembrane connexin segment.
  • HY-106268A
    Larazotide acetate
    Inhibitor 99.68%
    Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight junction regulator and reverses leaky junctions to their normally closed state.
  • HY-15204
    Tonabersat
    Modulator 98.36%
    Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system.
  • HY-106268
    Larazotide
    Inhibitor
    Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection.
  • HY-117275S1
    Meclofenamic acid-13C6
    Inhibitor
    Meclofenamic acid-13C6 is the 13C6 labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.
  • HY-117275A
    Meclofenamic acid sodium hydrate
    Inhibitor
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
  • HY-P1136A
    Gap19 TFA
    Inhibitor
    Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial.
  • HY-P1082
    Gap 26
    Inhibitor 99.90%
    Gap 26 is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.
  • HY-106225
    Rotigaptide
    Modulator 99.88%
    Rotigaptide (ZP123) is a novel and specific modulator of connexin 43 (Cx43). Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. Rotigaptide is a potent antiarrhythmic peptide (AAP) with improved stability and has the potential for the investigation of cardiac arrhythmias-specifically atrial fibrillation.
  • HY-10913A
    Danegaptide Hydrochloride
    Modulator 99.20%
    Danegaptide Hydrochloride (GAP-134 Hydrochloride) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
  • HY-114426A
    AT-1002 TFA
    Modulator 99.72%
    AT-1002 TFA, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.
  • HY-P1136C
    TAT-Gap19 TFA
    98.36%
    TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice.
  • HY-P1082A
    Gap 26 TFA
    Inhibitor 99.72%
    Gap 26 TFA is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.
  • HY-P1136B
    TAT-Gap19
    99.33%
    TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.
  • HY-10913
    Danegaptide
    Modulator
    Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
  • HY-114426
    AT-1002
    Modulator
    AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.
  • HY-P2275
    Peptide5
    Inhibitor
    Peptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury
  • HY-117275
    Meclofenamic acid
    Inhibitor
    Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.